A multicenter, first-night cross-over study demonstrating a 52% responder rate and sustained 28-day benefit in moderate-to-severe OSA
Backed by a multi center randomized study, iNAP showed a 52% responder rate with sustained benefits over 28 days—proving that comfort and clinical impact can go hand in hand.